Novartis Licenses Anti-PD1 Antibody Tislelizumab from BeiGene in US$2.2 B Deal

By Neha Madhwani & Michelle Liu

Pharma Deals Review: Vol 2021 Issue 2 (Table of Contents)

Published: 8 Feb-2021

DOI: 10.3833/pdr.v2021.i2.2591     ISSN: 1756-7874

Section: Research & Development



In another move to strengthen its immuno-oncology pipeline, Novartis has agreed to partner with BeiGene to develop and commercialise a PD-1 inhibitor, tislelizumab...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details